Speedus Corp.
Speedus Corp.
Your view on SPDE
Overview
What the company does, where it operates, and who runs it.
About Speedus Corp.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Shant S. Hovnanian
- Headquarters
- 1 Dag Hammarskjold Boulevard, Freehold, US
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Shant S. Hovnanian
- Headquarters
- 1 Dag Hammarskjold Boulevard, Freehold, US
Speedus Corp., through its subsidiaries, engages in the development of diagnostic decision support products and services for primary care physicians, pediatricians, cardiologists, and other healthcare professionals in the United States.
The company offers computer-aided medical devices and telemedicine based delivery systems, including Zargis Cardioscan device, a non-invasive diagnostic support solution that automatically analyzes acoustical data from a patient to determine whether or not the patient possesses a suspected diastolic or systolic murmur; ZargisTelemed portal; and Signal X6 device, which records heart and lung sounds from six adhesive acoustic sensors.
It also develops and markets ultra-high speed storage systems comprising JetX10 acceleration appliance, JetPod, and JetNode expansion chassis for server networks and other applications.
In addition, the company offers local multipoint distribution service license, an FCC commercial operating license, which covers between 150300 MHz of spectrum in the New York City area. Further, it holds investments in a portfolio of marketable securities and in equity and debt instruments of non-publicly held companies.
The company was formerly known as SPEEDUS.COM, Inc. and changed its name to Speedus Corp. in May 2002. Speedus Corp. was founded in 1995 and is based in Freehold, New Jersey.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Speedus Corp., and the rating behind it. SPDE last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Speedus Corp.. Starting points for Speedus Corp.: EPS -$0.72, beta 35.48 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Speedus Corp.. Speedus Corp. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Speedus Corp.. Trailing twelve-month EPS for Speedus Corp. stands at -$0.72. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Speedus Corp.. Speedus Corp. has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Speedus Corp. valued side by side against its closest peers. Speedus Corp. is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Speedus Corp., and how their positions are changing. At a $416 market value, institutional positions materially move Speedus Corp.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Speedus Corp. executives and directors. Shares of Speedus Corp. have traded between $0.0000 and $0.0001 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Speedus Corp.. Speedus Corp. is a $416 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Speedus Corp.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Speedus Corp.. Coverage tracks Speedus Corp. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.